NCT02941614

Brief Summary

Many breast cancer patients experience psychological distress during their cancer care journey. There are effective treatments for breast cancer patients experiencing distress, such as individual or group therapy, health education, and medication. Unfortunately, clinicians may not be aware of the symptoms of distress in their breast cancer patients, and some breast cancer patients who could benefit from referral to behavioral health specialists are overlooked. New guidelines recommend that all cancer patients be regularly screened for distress. However, there are unanswered questions about the impact of distress screening conducted on a large scale. Few studies have evaluated the impact of distress screening on important outcomes in breast cancer patients, such as patient experience and use of health care services, as compared to the usual care offered by the health care organization. In addition, oncology clinicians may be uncertain about the benefits of large-scale distress screening, and pilot screening programs have not been uniformly successful particularly in the community oncology setting. The overarching goals of this study are to assess the effectiveness of implementing a guideline-recommended distress screening program for newly diagnosed breast cancer patients on improving identification and referral to treatment for highly distressed breast cancer patients, to assess patient-reported outcomes, health services utilization, and implementation outcomes of the program. This study will address two main research questions: 1) Evaluate the effectiveness of a guideline-recommended distress screening program for breast cancer patients in improving identification of distressed patients, initiation and completion of referrals to behavioral health, and patient-reported and utilization outcomes as compared to usual care; 2) Identify the barriers, facilitators, and other implementation-related outcomes related to distress screening in the community oncology setting. Please note: This study did not require a DSMB, as it falls under the exception for low-risk behavioral studies.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,436

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2017

Typical duration for all trials

Geographic Reach
1 country

6 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 17, 2016

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 21, 2016

Completed
12 months until next milestone

Study Start

First participant enrolled

October 2, 2017

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2019

Completed
7 months until next milestone

Results Posted

Study results publicly available

July 7, 2020

Completed
Last Updated

July 7, 2020

Status Verified

June 1, 2020

Enrollment Period

2.2 years

First QC Date

October 17, 2016

Results QC Date

April 13, 2020

Last Update Submit

June 22, 2020

Conditions

Outcome Measures

Primary Outcomes (2)

  • Number of Participants Offered and Screened for Distress

    \# of newly diagnosed breast cancer patients offered and screened with the Patient Health Questionnaire 9 at their initial consult

    Patients assessed during initial consult - e.g. 1 day during 60 min consult

  • Number of Participants Offered an Appropriate Referral

    For patients who had screening done in Oncology, appropriate action for those with a medium/high PHQ-9 is a referral to social work, psychiatry, depression care management.

    Patients assessed during initial consult - e.g. 1 day during 60 min consult

Secondary Outcomes (4)

  • Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B)

    12 months

  • Breast Cancer Prevention Trial (BCPT) Symptom Checklist

    12 months

  • Number of Patients With Oncology Visit

    18 months

  • Number of Patients With Primary Care Visit

    18 months

Other Outcomes (2)

  • Number of Participants Utilizing Behavioral Health Services

    18 months

  • Number of Participants Utilizing Emergency and Urgent Care Services

    18 months

Study Arms (2)

Intervention

Newly diagnosed breast cancer patients will be offered a brief distress screening questionnaire, the Patient Health Questionnaire (PHQ), around the time of their breast cancer diagnosis and again at subsequent transitions in care as appropriate (e.g., the initiation of chemotherapy).

Behavioral: Distress screening

Control

Newly diagnosed breast cancer patients will experience usual care.

Interventions

A brief depression and anxiety screening instrument, the Patient Health Questionnaire-9 (PHQ-9), will be administered to newly diagnosed breast cancer patients in the Distress Screening arm.

Intervention

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Newly diagnosed breast cancer patients

You may qualify if:

  • Newly diagnosed with initial breast cancer, any stage, any histology type
  • Kaiser Permanente member for at least 100 days during study period

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (6)

Anaheim Medical Center

Anaheim, California, 92806, United States

Location

Baldwin Park Medical Center

Baldwin Park, California, 91706, United States

Location

South Bay - Harbor City Medical Center

Harbor City, California, 90710, United States

Location

Los Angeles Medical Center

Los Angeles, California, 90027, United States

Location

West Los Angeles Medical Center

Los Angeles, California, 90034, United States

Location

Woodland Hills Medical Center

Woodland Hills, California, 91364, United States

Location

Related Publications (2)

  • Hahn EE, Munoz-Plaza CE, Lyons LJ, Lee JS, Pounds D, La Cava S, Brasfield FM, Durna LN, Kwan KW, Beard DB, Ferreira A, Gould MK. Barriers and facilitators to implementation and sustainment of guideline-recommended depression screening for patients with breast cancer in medical oncology: a qualitative study. Support Care Cancer. 2023 Jul 12;31(8):461. doi: 10.1007/s00520-023-07922-0.

  • Hahn EE, Munoz-Plaza CE, Pounds D, Lyons LJ, Lee JS, Shen E, Hong BD, La Cava S, Brasfield FM, Durna LN, Kwan KW, Beard DB, Ferreira A, Padmanabhan A, Gould MK. Effect of a Community-Based Medical Oncology Depression Screening Program on Behavioral Health Referrals Among Patients With Breast Cancer: A Randomized Clinical Trial. JAMA. 2022 Jan 4;327(1):41-49. doi: 10.1001/jama.2021.22596.

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Limitations and Caveats

No limitations to report

Results Point of Contact

Title
Erin Hahn
Organization
Kaiser Permanente Southern California Department of Research and Evaluation

Study Officials

  • Erin E Hahn, PhD

    Kaiser Permanente

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 17, 2016

First Posted

October 21, 2016

Study Start

October 2, 2017

Primary Completion

November 30, 2019

Study Completion

November 30, 2019

Last Updated

July 7, 2020

Results First Posted

July 7, 2020

Record last verified: 2020-06

Data Sharing

IPD Sharing
Will not share

Locations